Diffusion magnetic resonance imaging with gadofosveset trisodium as a negative contrast agent for lymph node metastases assessment

Yamashita, Tomohiro; Takahara, Taro; Kwee, Thomas C.; Kawada, Shin-ichiro; Horie, Tomohiko; Inomoto, Chie; Hashida, Kazunobu; Yamamuro, Hiroshi; Myojin, Kazunori; Luijten, Peter R.; Imai, Yutaka

doi:10.1007/s11604-010-0513-2

Cited by 8 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Within this period, MR imaging has undergone a massive technologic evolution, with faster imaging sequences and cardiac and respiratory triggering, enabling good correlation with cytologic and/or histologic findings at a higher spatial and temporal resolution (64,83). To investigate the relationship of additional technologic progress within this period on the overall pooled estimates (Ablavar; Lantheus Medical Imaging, North Billerica, Mass), may hold additional benefits to further improve the diagnostic performance of MR imaging (79)(80)(81). Additionally, MR imaging does not expose patients and medical personnel to irradiation, is less invasive, and is less expensive than FDG PET/ CT (82).…”

Section: Evidence-based Practice: Meta-analysis Of Mr Imaging For Nodmentioning

confidence: 99%

The Diagnostic Value of MR Imaging in Determining the Lymph Node Status of Patients with Non–Small Cell Lung Cancer: A Meta-Analysis

Peerlings¹,

Troost²,

Nelemans³

et al. 2016

Radiology

View full text Add to dashboard Cite

Purpose To summarize existing evidence of thoracic magnetic resonance (MR) imaging in determining the nodal status of non-small cell lung cancer (NSCLC) with the aim of elucidating its diagnostic value on a per-patient basis (eg, in treatment decision making) and a per-node basis (eg, in target volume delineation for radiation therapy), with results of cytologic and/or histologic examination as the reference standard. Materials and Methods A systematic literature search for original diagnostic studies was performed in PubMed, Web of Science, Embase, and MEDLINE. The methodologic quality of each study was evaluated by using the Quality Assessment of Diagnostic Accuracy Studies 2, or QUADAS-2, tool. Hierarchic summary receiver operating characteristic curves were generated to estimate the diagnostic performance of MR imaging. Subgroup analyses, expressed as relative diagnostic odds ratios (DORs) (rDORs), were performed to evaluate whether publication year, methodologic quality, and/or method of evaluation (qualitative [ie, lesion size and/or morphology] vs quantitative [eg, apparent diffusion coefficients in diffusion-weighted images]) affected diagnostic performance. Results Twelve of 2551 initially identified studies were included in this meta-analysis (1122 patients; 4302 lymph nodes). On a per-patient basis, the pooled estimates of MR imaging for sensitivity, specificity, and DOR were 0.87 (95% confidence interval [CI]: 0.78, 0.92), 0.88 (95% CI: 0.77, 0.94), and 48.1 (95% CI: 23.4, 98.9), respectively. On a per-node basis, the respective measures were 0.88 (95% CI: 0.78, 0.94), 0.95 (95% CI: 0.87, 0.98), and 129.5 (95% CI: 49.3, 340.0). Subgroup analyses suggested greater diagnostic performance of quantitative evaluation on both a per-patient and per-node basis (rDOR = 2.76 [95% CI: 0.83, 9.10], P = .09 and rDOR = 7.25 [95% CI: 1.75, 30.09], P = .01, respectively). Conclusion This meta-analysis demonstrated high diagnostic performance of MR imaging in staging hilar and mediastinal lymph nodes in NSCLC on both a per-patient and per-node basis. (©) RSNA, 2016 Online supplemental material is available for this article.

show abstract

Section: Evidence-based Practice: Meta-analysis Of Mr Imaging For Nodmentioning

confidence: 99%

The Diagnostic Value of MR Imaging in Determining the Lymph Node Status of Patients with Non–Small Cell Lung Cancer: A Meta-Analysis

Peerlings¹,

Troost²,

Nelemans³

et al. 2016

Radiology

View full text Add to dashboard Cite

show abstract

“…Preliminary studies have shown promise for the use of DWI to detect metastatic disease in lymph nodes 96,97 . To date there is only one published study evaluating its ability to evaluate axillary lymph nodes in patients with newly diagnosed breast cancer, which reported ADC values were significantly lower in metastatic versus benign axillary nodes 98 .…”

Section: Potential Clinical Applicationsmentioning

confidence: 99%

Diffusion Weighted Magnetic Resonance Imaging of the Breast

Partridge

McDonald

2013

Magnetic Resonance Imaging Clinics of North America

153

View full text Add to dashboard Cite

Synopsis There has been increasing interest in the use of diffusion weighted MRI (DWI) for breast imaging. This technique has shown promise for improving the positive predictive value of breast MRI for detection of breast cancer, evaluating tumor response to neoadjuvant chemotherapy, and as a non-contrast MRI alternative for breast cancer screening. However, there is currently no standardized approach to DWI of the breast and data quality varies widely. Prior to implementing DWI into clinical practice, it is important to understand the pertinent technical considerations and current evidence of clinical applications of DWI of the breast. This article provides an overview of basic principles of DWI, optimization of breast DWI protocols, imaging features of benign and malignant breast lesions, promising clinical applications, and potential future directions.

show abstract

“…Vasovist R , a whole-body MRI image agent has been developed using Gd-albumin complex for detecting malignant lesions in humans. 65,66 Fluorescent imaging is another promising tool for cancer diagnosis. A nanocolloidal albumin-IRDye 800CW, with the size between 10-20 nm, has been synthesized by chemically conjugating fluorescent dye IRDye 800CW onto albumin.…”

Section: Biopolymermentioning

confidence: 99%

Polymeric Nanosystems for Targeted Theranostics

Li¹,

Wen²,

Dong³

et al. 2016

Nanomaterials for Tumor Targeting Theranostics

View full text Add to dashboard Cite

Past several years have seen extensive developments of a variety of theranostic nanosystems. Significant advances on polymeric theranostic nanosystem have been made in image-guided drug delivery taking advantage of the versatility, adaptability and biocompatibility of the rationally designed polymers. In this chapter, the critical issues confronted in the design, synthesis, and characterization of polymeric nanosystem are addressed. An overview is further given on the applications of polymeric nanosystem in biomedicine. In particular, the discussions are focused on some of the key elements of theranostics in terms of fluorescent imaging, drug storage, and controlled delivery. Some novel drug release behavior based on intelligent triggering mechanisms is also discussed. IntroductionThe cure of the cancer critically depends on the early detection and timely medical treatment. The survival rate of patients with breast cancer is approximately 90 %, if it can be diagnosed at an early stage before occurrence of metastasis to distant tissues, organs or lymph nodes. In contrast, the survival rate significantly decreases to 20%, if discovered at a later stage.

show abstract

Diffusion magnetic resonance imaging with gadofosveset trisodium as a negative contrast agent for lymph node metastases assessment

Cited by 8 publications

References 19 publications

The Diagnostic Value of MR Imaging in Determining the Lymph Node Status of Patients with Non–Small Cell Lung Cancer: A Meta-Analysis

The Diagnostic Value of MR Imaging in Determining the Lymph Node Status of Patients with Non–Small Cell Lung Cancer: A Meta-Analysis

Diffusion Weighted Magnetic Resonance Imaging of the Breast

Polymeric Nanosystems for Targeted Theranostics

Contact Info

Product

Resources

About